tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

IMVT Stock Latest News

Immunovant rumor highlighted in Betaville alert
The FlyImmunovant rumor highlighted in Betaville alert
6d ago
IMVT
Immunovant initiated with a Hold at Truist
PremiumThe Fly
Immunovant initiated with a Hold at Truist
22d ago
IMVT
Immunovant price target lowered to $33 from $37 at JPMorgan
PremiumThe Fly
Immunovant price target lowered to $33 from $37 at JPMorgan
1M ago
IMVT
3 Best Stocks to Buy Now, 9/4/2025, According to Top Analysts
PremiumMarket News
3 Best Stocks to Buy Now, 9/4/2025, According to Top Analysts
2M ago
IVA
IMVT
Immunovant’s Batoclimab Shows Promising Results in Phase 2 Study for Graves’ Disease, Earning Buy Rating
PremiumRatings
Immunovant’s Batoclimab Shows Promising Results in Phase 2 Study for Graves’ Disease, Earning Buy Rating
2M ago
IMVT
Immunovant’s Promising Clinical Data and Strategic Advancements Drive Buy Rating
PremiumRatingsImmunovant’s Promising Clinical Data and Strategic Advancements Drive Buy Rating
2M ago
IMVT
Immunovant Announces Promising Graves’ Disease Study Results
Premium
Company Announcements
Immunovant Announces Promising Graves’ Disease Study Results
2M ago
8K
IMVT
Immunovant: 80% of patients demonstrate response in Graves’ disease trial
Premium
The Fly
Immunovant: 80% of patients demonstrate response in Graves’ disease trial
2M ago
IMVT
Optimistic Buy Rating for Immunovant: Strategic Positioning and Promising Monotherapy Potential
PremiumRatings
Optimistic Buy Rating for Immunovant: Strategic Positioning and Promising Monotherapy Potential
2M ago
IMVT
Immunovant Stockholders Approve Key Governance Decisions
PremiumCompany Announcements
Immunovant Stockholders Approve Key Governance Decisions
2M ago
8K
IMVT
Immunovant’s Promising Pipeline and Strategic Focus Justify Buy Rating
PremiumRatings
Immunovant’s Promising Pipeline and Strategic Focus Justify Buy Rating
3M ago
IMVT
Immunovant price target lowered to $30 from $33 at BofA
PremiumThe Fly
Immunovant price target lowered to $30 from $33 at BofA
3M ago
IMVT
Immunovant price target lowered to $37 from $40 at JPMorgan
PremiumThe FlyImmunovant price target lowered to $37 from $40 at JPMorgan
3M ago
IMVT
Immunovant’s Promising Pipeline and Strong Financial Position Signal a Buy Rating
Premium
Ratings
Immunovant’s Promising Pipeline and Strong Financial Position Signal a Buy Rating
3M ago
IMVT
Immunovant’s Promising Advances in Graves’ Disease Treatment Drive Buy Rating
Premium
Ratings
Immunovant’s Promising Advances in Graves’ Disease Treatment Drive Buy Rating
3M ago
IMVT
Immunovant Reports Progress and Financial Results
PremiumCompany Announcements
Immunovant Reports Progress and Financial Results
3M ago
IMVT
Immunovant’s Strategic Advancements and Clinical Progress Justify Buy Rating
PremiumRatings
Immunovant’s Strategic Advancements and Clinical Progress Justify Buy Rating
3M ago
IMVT
Immunovant price target lowered to $57 from $58 at Citi
PremiumThe Fly
Immunovant price target lowered to $57 from $58 at Citi
3M ago
IMVT
Immunovant’s IMVT-1402: Promising Clinical Advancements and Strong Buy Rating Despite Increased Operational Costs
PremiumRatings
Immunovant’s IMVT-1402: Promising Clinical Advancements and Strong Buy Rating Despite Increased Operational Costs
3M ago
IMVT
Immunovant reports Q EPS (71c), consensus (67c)
PremiumThe FlyImmunovant reports Q EPS (71c), consensus (67c)
3M ago
IMVT
Immunovant Appoints Eric Venker as New CEO
Premium
Company Announcements
Immunovant Appoints Eric Venker as New CEO
3M ago
8K
IMVT
Immunovant price target raised to $18 from $17 at UBS
Premium
The Fly
Immunovant price target raised to $18 from $17 at UBS
3M ago
IMVT

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >